Small molecule · Agonist of retinoid X receptor alpha (RXRA), retinoid X receptor beta (RXRB) and retinoid X receptor gamma (RXRG) · developed by Bausch
ApprovedFDA, Dec 1999
1Registered trials
What is Bexarotene?
Bexarotene is a retinoid that selectively binds and activates retinoid X receptor subtypes (RXRα, RXRβ, RXRγ). Activated RXRs act as transcription factors regulating genes that control cellular differentiation and proliferation. It is used in cutaneous T-cell lymphoma and has been studied in parapsoriasis.
Summary written with AI from the sources listed at the end of this page.
At a glance
Also known as
Targretin, LG-100069, LGD-1069
Drug type
Small molecule
Targets
retinoid X receptor alpha (RXRA), retinoid X receptor beta (RXRB), retinoid X receptor gamma (RXRG)
Mechanism
Agonist of retinoid X receptor alpha (RXRA), retinoid X receptor beta (RXRB) and retinoid X receptor gamma (RXRG)
Pathways
nuclear receptor transcription regulation, cellular differentiation, cellular proliferation, RXR heterodimer signaling with RAR, VDR, TR and PPAR
From the indications section of the FDA label (version of Apr 30, 2020). Read the full label for the exact wording, limitations and safety information.
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.